SGLT2 inhibitors and diabetic retinopathy: Insights from the management of nephropathy.
作者信息
Varughese Maria S, Varadhan Lakshminarayanan
机构信息
University of Sheffield Medical School, Royal Hallamshire Hospital, Sheffield, UK.
University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, North Staffordshire, UK.
出版信息
Eye (Lond). 2025 Feb;39(2):213-214. doi: 10.1038/s41433-024-03472-9. Epub 2024 Nov 12.
Abstract
摘要
相似文献
1
SGLT2 inhibitors and diabetic retinopathy: Insights from the management of nephropathy.
Eye (Lond). 2025 Feb;39(2):213-214. doi: 10.1038/s41433-024-03472-9. Epub 2024 Nov 12.
2
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy.
Pharmacol Ther. 2023 Sep;249:108503. doi: 10.1016/j.pharmthera.2023.108503. Epub 2023 Jul 24.
3
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Diabetes Obes Metab. 2022 Nov;24(11):2159-2168. doi: 10.1111/dom.14801. Epub 2022 Jul 15.
4
Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.
Ren Fail. 2023 Dec;45(1):2217287. doi: 10.1080/0886022X.2023.2217287.
5
New interpretation of diabetic nephropathy or diabetic kidney disease from kidney biopsy: review article.
Clin Exp Nephrol. 2025 Mar 24. doi: 10.1007/s10157-025-02661-4.
6
Cardiorenal Benefits of SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Concomitant Hypertension.
Cardiorenal Med. 2025;15(1):496-509. doi: 10.1159/000545622. Epub 2025 Apr 21.
7
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Endocrinol Metab (Seoul). 2021 Apr;36(2):388-400. doi: 10.3803/EnM.2020.912. Epub 2021 Mar 31.
8
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Lancet Diabetes Endocrinol. 2016 May;4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8. Epub 2016 Mar 18.
9
The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study.
Cardiovasc Diabetol. 2025 Feb 28;24(1):97. doi: 10.1186/s12933-025-02643-6.
10
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
Diabetes Obes Metab. 2022 Aug;24(8):1448-1457. doi: 10.1111/dom.14702. Epub 2022 Jun 6.
引用本文的文献
1
Hybrid closed loop and intensive insulin delivery technology: Reviewing the effect of improving 'time in range' glucose levels on diabetic retinopathy.
Eye (Lond). 2025 Apr;39(6):1028-1030. doi: 10.1038/s41433-025-03730-4. Epub 2025 Feb 20.
本文引用的文献
1
Exploring the unexplored: identifying knowledge gaps in novel pharmacological treatments for diabetic retinopathy.
Eye (Lond). 2025 Jan;39(1):192-194. doi: 10.1038/s41433-024-03349-x. Epub 2024 Sep 17.
2
Targeting pericyte retention in Diabetic Retinopathy: a review.
Ann Med. 2024 Dec;56(1):2398200. doi: 10.1080/07853890.2024.2398200. Epub 2024 Sep 13.
3
Individual treatment effects of sodium-glucose co-transporter-2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real-world data.
Diabetes Obes Metab. 2024 Oct;26(10):4418-4428. doi: 10.1111/dom.15793. Epub 2024 Jul 22.
4
Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study.
Diabetes Obes Metab. 2024 Oct;26(10):4386-4396. doi: 10.1111/dom.15788. Epub 2024 Jul 19.
5
Newer treatments for diabetes mellitus: A caveat with rapid glycaemic improvement and caution regarding changes in retinopathy screening guidelines within the UK NHS programme.
J R Coll Physicians Edinb. 2024 Jun;54(2):178-179. doi: 10.1177/14782715241257970. Epub 2024 May 27.
6
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.
Ophthalmol Retina. 2024 Oct;8(10):943-952. doi: 10.1016/j.oret.2024.05.003. Epub 2024 May 11.
7
Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study.
Am J Ophthalmol. 2024 Sep;265:39-47. doi: 10.1016/j.ajo.2024.04.010. Epub 2024 Apr 17.
8
The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium-Glucose Transporter 2 Inhibitors.
Diabetes. 2024 Jul 1;73(7):1153-1166. doi: 10.2337/db22-0970.
9
Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
Diabetologia. 2024 Jul;67(7):1271-1282. doi: 10.1007/s00125-024-06132-5. Epub 2024 Apr 8.
10
Sodium-glucose co-transporter 2 inhibitor therapy reduces the administration frequency of anti-vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti-vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database.
Diabetes Obes Metab. 2024 Apr;26(4):1510-1518. doi: 10.1111/dom.15454. Epub 2024 Jan 19.
Zotero 插件